ThinHeal expands peptide API push with GMP plant and DMF filings

Oct. 30, 2026
ThinHeal expands peptide API push with GMP plant and DMF filings
By AI, Created 05:45 UTC, Oct 30, 2026, AGP -

Hangzhou ThinHeal Pharma-Tech says it is scaling up peptide API research and production as demand rises across pharmaceutical and cosmetic markets. The company has added GMP capacity, filed FDA DMFs and broadened its portfolio of therapeutic and cosmetic peptides.

Why it matters: - ThinHeal is building for a peptide market that is growing in pharmaceutical development and cosmetic ingredient applications. - The company’s mix of APIs, CDMO services and cosmetic peptide work positions it across multiple parts of the peptide supply chain. - The expansion matters for drug developers and ingredient buyers that need consistent production, documentation and specialized synthesis.

What happened: - Hangzhou ThinHeal Pharma-Tech Co., Ltd. said it is strengthening its global presence through peptide API research and production. - The company was founded in 2019 and operates in pharmaceutical peptide APIs, CDMO services and cosmetic peptide development and production. - ThinHeal said its production capacity for chemically synthesized peptides has reached several tons. - The company operates a research and development center and a dedicated production base. - ThinHeal said it achieved ISO 9001 certification in 2022. - ThinHeal launched a 20,000-square-meter GMP facility in 2024. - ThinHeal filed three Drug Master Files with the U.S. Food and Drug Administration in 2024. - ThinHeal said its GLP-1 API and finished dosage form preparations were advanced for global market requirements in 2025. - The company said it obtained three WC certificates and reached an annual production capacity of 3,000 kilograms in 2026.

The details: - ThinHeal’s therapeutic peptide API portfolio includes GLP-1 analogues, GLP-2 analogues, gastrointestinal peptides and other therapeutic peptide APIs. - Listed products include semaglutide, tirzepatide, liraglutide, linaclotide, retatrutide, eptifibatide, dulaglutide, deslorelin and triptorelin. - Semaglutide is a GLP-1 receptor agonist. - Tirzepatide acts on both GIP and GLP-1 receptors. - Linaclotide is part of the gastrointestinal peptide category. - Eptifibatide is associated with research and pharmaceutical applications involving platelet aggregation. - ThinHeal also develops cosmetic peptides. - Copper tripeptide, also known as GHK-Cu, is one of the company’s listed cosmetic peptide products. - ThinHeal said its research system includes complex peptide and peptoid synthesis and modification, peptide fragment design and synthesis, and multiple separation and purification technologies. - The company said its R&D team has more than 130 members, with nearly 20% holding doctoral or master’s degrees. - ThinHeal said its core research personnel have more than 20 years of experience in peptide drug development. - The company uses both solid-phase and liquid-phase chemical synthesis technologies.

Between the lines: - ThinHeal is signaling a strategy built around integration rather than a single-product peptide business. - The company is pairing manufacturing capacity with research, purification and documentation capabilities that matter in regulated markets. - A broader portfolio may help ThinHeal serve pharmaceutical developers and cosmetic formulators with different quality and scale requirements. - The CDMO model suggests ThinHeal is aiming to support projects from early development through manufacturing.

What’s next: - ThinHeal said it will continue expanding its peptide synthesis, API manufacturing and customized development services. - The company is targeting international pharmaceutical and ingredient markets as peptide demand evolves. - Future growth will likely depend on process consistency, regulatory documentation and scaling production across product categories.

The bottom line: - ThinHeal is trying to turn peptide R&D into a broader manufacturing platform, with pharma, CDMO and cosmetic lines all under one roof. - More information is available on the company’s official website.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Science Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Science Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.